Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8512910 | 1.00 | SPR (0.32) | SPRDPP4KDM2BGRIN2BDPP8 | |
| SCHEMBL23523517 | 1.00 | SPR (0.32) | SPRDPP4KDM2BGRIN2BDPP8 | |
| SCHEMBL27948 | 0.82 | — | — | |
| SCHEMBL18711402 | 0.82 | CHRNB2 (0.48) | SPRDPP4KDM2BDPP8DPP9 | |
| SCHEMBL1439352 | 0.79 | — | — | |
| SCHEMBL26918602 | 0.79 | — | — | |
| SCHEMBL18701741 | 0.77 | DPP4 (0.39) | SPRDPP4KDM2BDPP8DPP9 | |
| SCHEMBL13000980 | 0.77 | DPP4 (0.48) | SPRDPP4KDM2BDPP8DPP9 | |
| SCHEMBL3394595 | 0.77 | DPP4 (0.48) | SPRDPP4KDM2BDPP8DPP9 | |
| SCHEMBL23523189 | 0.75 | NR1H2 (0.36) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4353309-A1 | PHENYL UREA DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2024-04-17 | — | — | EP | disclosed |
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023204291-A1 | BICYCLOAMINE CARBOXAMIDE DERIVATIVE | 住友ファーマ株式会社 | 2023-10-26 | — | — | WO | disclosed |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| EP-4139303-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4139302-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220213069-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2022-07-07 | — | — | US | disclosed |
| US-11299481-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2021216951-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021216949-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20210188820-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| US-8865738-B2 | 5-membered heterocyclic compound cyclopenta[C]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2014-10-21 | — | — | US | disclosed |
| EP-2429998-B1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820757-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | SPR 1305/4885DPP4 679/4885KDM2B 2748/4885 |
| US-20230183218-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | SPR 900/4885DPP4 920/4885KDM2B 3479/4885 |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | SPR 970/4885DPP4 1029/4885KDM2B 3379/4885 |
| US-20240116902-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | SPR 1305/4885DPP4 679/4885KDM2B 2748/4885 |
| US-11299481-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM4 | SPR 1305/4885DPP4 679/4885KDM2B 2748/4885 |
| US-20220213069-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | SPR 1305/4885DPP4 679/4885KDM2B 2748/4885 |
| US-20210188820-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | SPR 1305/4885DPP4 679/4885KDM2B 2748/4885 |
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CA9, SCN9A, CCR9 | SPR 3047/4885DPP4 3229/4885KDM2B 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.